A longitudinal and cross-sectional study of Epstein-Barr virus DNA load: a possible predictor of AIDS-related lymphoma in HIV-infected patients by Hijlkema, S.H. (S. H.) et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=infd20
Infectious Diseases
ISSN: 2374-4235 (Print) 2374-4243 (Online) Journal homepage: http://www.tandfonline.com/loi/infd20
A longitudinal and cross-sectional study ofEpstein-
Barr virus DNA load: a possible predictor of AIDS-
related lymphoma in HIV-infected patients
S. H. Hijlkema, J. J. A. van Kampen, J. J. C. Voermans, M. Y. E. den Oudsten, J.
Doorduijn, P. J. van Lugtenburg, D. A. M. C. van de Vijver & M. E. van der Ende
To cite this article: S. H. Hijlkema, J. J. A. van Kampen, J. J. C. Voermans, M. Y. E. den
Oudsten, J. Doorduijn, P. J. van Lugtenburg, D. A. M. C. van de Vijver & M. E. van der Ende
(2018): A longitudinal and cross-sectional study ofEpstein-Barr virus DNA load: a possible
predictor of AIDS-related lymphoma in HIV-infected patients, Infectious Diseases, DOI:
10.1080/23744235.2018.1508884
To link to this article:  https://doi.org/10.1080/23744235.2018.1508884
© 2018 Society for Scandinavian Journal of
Infectious Diseases
Published online: 14 Oct 2018.
Submit your article to this journal 
Article views: 55
View Crossmark data
INFECTIOUS DISEASES,
2018; VOL. 0,
NO. 0, 1–6
https://doi.org/10.1080/23744235.2018.1508884
ORIGINAL ARTICLE
A longitudinal and cross-sectional study of
Epstein-Barr virus DNA load: a possible predictor of
AIDS-related lymphoma in HIV-infected patients
S. H. Hijlkemaa, J. J. A. van Kampenb, J. J. C. Voermansb, M. Y. E. den Oudstena, J. Doorduijnc,
P. J. van Lugtenburgc, D. A. M. C. van de Vijverb and M. E. van der Endea
aDepartment of Internal Medicine and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands; bDepartment of
Viroscience, Erasmus MC, Rotterdam, The Netherlands; cDepartment of Haematology, Erasmus MC Cancer Institute, Rotterdam,
The Netherlands
ABSTRACT
Introduction: HIV-infected patients are more than 100-fold greater at risk for developing malignant AIDS-related lymph-
oma (ARL) compared to the general population. Most ARLs are EBV related. The main purpose of this study was to investi-
gate whether a high peak EBV DNA load in HIV-infected patients is predictive of ARL, including classical
Hodgkin lymphoma.
Methods: From an ongoing prospective HIV positive cohort study, we conducted a case-control study between 2004 and
2016 among patients from whom at least one EBV DNA load in serum or plasma was available. We compared peak EBV
DNA load between patients with (49 cases) and without ARL (156 controls).
Results: The geometric mean of the peak EBV DNA load measured before diagnosis of malignant lymphoma was
52,565 IU/mL in EBER-positive lymphoma patients vs. 127 IU/mL in controls (p< .001). Patients with EBV DNA loads
>100,000 IU/mL have an increased risk for diagnosis of malignant lymphoma compared to patients with EBV DNA loads
100,000 IU/mL (adjusted OR 12.53; 95%CI: 4.08; 38.42). In the longitudinal study, including 13 patients with at least three
left-over plasma samples available for retesting, measurements of EBV-DNA during the preceding 12 months proved to be
of poor value for predicting subsequent lymphoma diagnosis.
Conclusions: A EBV DNA load >100,000 IU/mL can be useful in clinical setting to accelerate time to diagnosis and treat-
ment. EBV-DNA loads in samples taken during the preceding year of ARL diagnosis showed to be of poor predictive value.
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Introduction
Before the era of combined antiretroviral therapy
(cART), HIV-infected patients were at more than hun-
dred-fold greater risk of developing non-Hodgkin
lymphoma and more than seven-fold greater risk of
developing classical Hodgkin lymphoma compared to
the general population [1]. Despite the declining inci-
dence of AIDS-related lymphoma (ARL) since the intro-
duction of cART [2,3], it constitutes >50% of all AIDS-
related malignancies [4,5] and remains the main cause
of AIDS-related deaths in HIV infected adults [5,6].
Epstein-Barr virus (EBV) is considered to be involved in
the pathogenesis in around half of all ARL [7] and in
nearly all cases of HIV-associated Hodgkin lymphoma
[7–9]. Multiple studies reported on the value of EBV
DNA load in plasma as a prognostic marker of ARL
treatment [10–13]. The extent to which EBV-DNA is
elevated in serum, plasma or blood before, at the
time, and after ARL diagnosis is still insufficiently
explored [12,13]. The main purpose of this study was
to investigate whether a high peak EBV DNA load in
HIV-infected patients is predictive of ARL, including
classical Hodgkin lymphoma.
Methods
Study population
Stored EBV-DNA load samples from HIV-infected patients
who were in care of our hospital from January 2004 to
August 2016 were identified in the virology laboratory.
We retrieved patients data from the HIV Monitoring
Foundation ATHENA cohort database. This cohort
includes data obtained from all HIV-infected patients in
care from 1997 onward in the Erasmus Medical Center
Rotterdam. Informed consent was obtained from all indi-
viduals [14]. Data that were not available were marked
as missing data. CD4þ cell count and plasma HIV RNA
load assessed six months prior to or after peak EBV DNA
were collected. Patients with missing quantitative EBV
DNA and patients lost to follow-up were excluded. To
improve power of the study, for each case four HIV posi-
tive controls without ARL were randomly selected from
the database of the virology laboratory. In patients with
at least three stored surplus serum or plasma samples
available within 12 months before ARL diagnosis, we
retested the samples for EBV-DNA in order to study the
course of EBV viral load one year before ARL diagnosis.
Samples
EBV DNA load was measured using an internal con-
trolled [15] quantitative real-time Taqman PCR based on
Niesters et al. [16] and LC480-II (Roche Applied Science,
Almere, The Netherlands).
Between January 2004 and October 2015, EBV DNA
loads were measured in copies/mL. To reliably compare
the EBV loads between different laboratories, from
October 2015 onwards, the qPCR was standardized
using the 1st WHO International Standard and validated
according to the ISO15189:2003 norm, including sensitiv-
ity, specificity, LLOD and a clinical validation. From here
on, the viral loads were measured in IU/mL.
The conversion factor between copies/mL and IU/mL
was determined using positive samples from the clinical
validation data (n¼ 39). The mean viral load difference
between both methods was 0.16 log, SD¼ 0.28. Also,
Bland and Altman plot and a paired, two-tailed t-test
were performed. The results, Y¼ 0.0192xþ 0.147,
R2¼ 0.0114 and 0.00199, respectively, confirmed that
there was no significant difference between the two
methods and the conversion factor was stated as one.
When multiple samples were available for a patient,
the highest EBV DNA load, i.e. peak EBV DNA load,
measured before diagnosis of malignant lymphoma was
taken into account. Samples with undetectable EBV DNA
load were assigned half of the lower limit of detection
(50 IU/mL) [17]. Plasma HIV-1 RNA loads 100,000 copy/
mL were presented as 100,000 copy/mL and samples
with undetectable HIV-1 RNA were assigned half of the
lower limit of quantification (50 copies/mL).
EBV-encoded RNA (EBER)
To define whether malignant lymphomas were truly
EBV-related, in situ hybridization targeting EBER was per-
formed on lymphoma tissue in 38/49 of the patients
(77.6%). If EBER examination was not performed on
lymphoma tissue, patients were not included in the ana-
lysis evaluating the mean difference in EBER-positive
lymphoma patients, EBER-negative lymphoma patients
and controls.
Statistical analysis
We performed logarithmic transformation of EBV DNA
loads in order to obtain a normally distributed variable.
Mean differences in peak EBV DNA loads between EBER-
positive malignant lymphoma patients, EBER-negative
malignant lymphoma patients and controls were
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measured using a parametric one-way analysis of vari-
ance (one-way ANOVA). If assumptions of equality of
variances were not met, Welch’s test was performed.
Post hoc test was performed to evaluate which groups
reached significant mean differences. Risk estimations
were calculated with cross-tabulations and presented as
odds ratios. Adjusted odds ratios and their 95% confi-
dence interval were calculated using a binary logistic
regression model. Age at peak EBV DNA load, sex, CD4þ
cell count assessed six months prior or after peak EBV
DNA load and nadir CD4þ cell count was considered
confounders based on current literature. Furthermore,
we performed receiver operating characteristic (ROC)
analysis to estimate the area under the curve (AUC) and
asses the accuracy of EBV DNA load as a predictive
marker of ARL. An optimal EBV DNA load cut-off value
predicting lymphoma in HIV-positive adults was deter-
mined from the ROC curve using the coordinates in
which sensitivity and specificity were most valid. Positive
predictive values were taken into account as well.
Statistical analysis was performed using IBM SPSS
Statistics version 21 (Armonk, NY).
Results
Patient characteristics
A total of 511 HIV-positive patients with plasma samples
were available. Forty-nine patients with historically con-
firmed ARL were eligible. Randomly selected controls
consisted of 156 patients. Patient characteristics are
shown in Table 1. ARL patients were older compared to
controls (median 47 years vs. 42 years), more likely to
be male (88% vs. 68%), and more often originating from
Europe (71% vs. 49.4%). Both groups had similar low
CD4þ cell counts at the time of ARL diagnosis and were
comparable concerning cART usage and HIV RNA sup-
pression when peak EBV-DNA loads were obtained.
Median peak EBV DNA loads were substantially different
between cases and controls (Mann–Whitney’s test,
p< .001), 11,100 IU/mL (interquartile range: 337; 258,500)
and 25 IU/mL (interquartile range: 25; 675), respectively.
Almost 35% of ARL patients had an EBV DNA load
>100,000 IU/mL, compared to merely 3% of controls.
Prior opportunistic infections occurred in 40% of con-
trols in contrast to 16% in ARL patients (Pearson’s chi-
square, p¼ .002).
Lymphoma subtypes
Nearly half of all cases were diffuse large B-cell lymph-
oma (21 cases) of whom 52% were EBV-related.
Lymphoma types with the highest percentage of EBER
positivity were primary effusion lymphoma (75%) and
Hodgkin lymphoma (66.7%).
EBER positive and negative ARL
Figure 1 shows median and interquartile ranges of loga-
rithmic transformed EBV DNA loads of EBER-positive
lymphoma patients (n¼ 28), EBER-negative lymphoma
patients (n¼ 10) and controls (n¼ 156). In 11 ARL
patients, EBER data were missing. The geometric mean
of the peak EBV DNA load measured before diagnosis of
ARL was 52.565 IU/mL in EBER-positive lymphoma
patients and 127 IU/mL in controls (p<.001). The geo-
metric mean in the EBER-negative group was 430 IU/mL,
which was significantly different from EBV DNA loads in
the EBER-positive group (p¼ .001). No significant differ-
ence was observed between EBER-negative lymphoma
patients and controls (p¼ .44).
Table 1. Patient characteristics.
Lymphoma patients (n¼ 49) Controls (n¼ 156)
Agea 47 (41–56) 42 (34–50)
Male gender 87.8 67.9
EBER performed 57.1 –
Peak EBV DNA load, IU/mL 11,100 (337–258,500) 25 (25–675)
<50 12.2 61.5
50–100,000 53.1 35.3
>100,000 34.7 3.2
CD4þ cell count, 109/Lb 0.15 (0.03–0.22) 0.13 (0.03–0.34)
Nadir CD4þ cell count, 109/L 0.07 (0.02–0.16) 0.05 (0.02–0.18)
HIV RNA load copy/mLb 250 (25–100,000) 6580 (55–100,000)
<50 32.7 24.4
50 67.3 75.6
cART >4 weeks 57.1 41.7
Prior opportunistic infection 16.3 40.4
European 71.4 49.4
Results are expressed as median (interquartile range) or %.
aAge at peak EBV DNA load measurement.
bCD4þ cell count and HIV RNA load measured 6 months prior to or after EBV measurement.
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Risk of malignant lymphoma
HIV-infected adults with detectable EBV DNA loads in
plasma or serum were at increased risk of ARL, com-
pared to patients with undetectable EBV DNA loads
(odds ratio 11.47; 95% confidence interval 4.60; 28.75).
In addition, when using a cut-off of >100,000 IU/mL, the
risk on ARL further increased (odds ratio 16.04; 95% con-
fidence interval 5.52; 46.66). Adjusted odds ratios were
10.57 (95% confidence interval 3.99; 28.00, R-square
0.324) and 12.53 (95% confidence interval 4.08; 38.42,
R-square 0.238).
Predictive biomarker
The ROC curve showed an AUC of 0.814 (p< .001).
When a cut-off point of 367,500 IU/mL was used we
achieved the highest specificity (71.2%) and sensitivity
(75.5%), with a corresponding positive predictive value
of 45%. When a cut-off point of 50 IU/mL (i.e. detectable
EBV DNA load) was used, the corresponding positive
predictive value was 41.7%, specificity was 61.5% and
sensitivity was 87.8%. A cut-off point of 100,000 IU/mL
showed a high specificity (96.8%) and positive predictive
value (77.3%), but sensitivity (34.7%) was low.
Course of plasma EBV DNA load 12 months before
ARL diagnosis
Thirteen patients were identified with at least three
available plasma samples for testing of EBV DNA load
during 12 months before ARL diagnosis (Figure 2).
One patient never showed a detectable EBV-DNA (L-1),
one patient showed several bursts of EBV DNA load
already six years prior to ARL diagnosis (L-2). The other
11 patients (L3–L13), except one (L9), had detectable
EBV-DNA loads (median 2900 IU/mL) which were lower
than EBV-DNA loads at the time of ARL diagnosis
(median 68,800 IU/mL). L9 showed a variable bursting
course of EBV-DNA during the year before ARL diagno-
sis. In this longitudinal group of 13 patients, the median
time of cART usage before ARL diagnosis was 14
Figure 1. Log-transformed peak EBV DNA load distribution of cases and controls.
Figure 2. Plasma EBV DNA (squares) and HIV RNA (circles) load 12
months before ARL diagnosis.
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months. In 10/13 patients, HIV-RNA was well suppressed.
The nadir CD4þ before start cART was median
70 cells/mm3.
Discussion
EBV-DNA loads in cross-sectional study
In the present study, we investigated the predictive
value of EBV DNA loads in plasma. We showed that HIV-
infected adults with peak EBV DNA loads >50 IU/mL in
plasma or serum are at increased risk of ARL. This is in
agreement with Fan et al. who found in a study of 48
HIV-infected patients with ARL that EBV-DNA >2500
copies/mL strongly correlated with the presence of
lymphoma [12]. A more recent study from Tanaka et al.,
showed that median EBV-DNA loads in peripheral blood
mononuclear cells (PBMCs) at the time of ARL diagnosis
in 17 HIV positive patients was significantly higher (1.3
copy/106 cells) compared to EBV DNA loads in HIV posi-
tive patients with opportunistic infections (0.1 copy/106
cells) (p¼ .002) or in HIV negative controls (EBV-DNA
undetectable) (p<.001) [11]. Bonnet et al., who studied
14 HIV positive patients with ARL, showed that EBV DNA
load in whole blood is of poor value for ARL diagnosis,
but suggested it to be useful as a marker for ARL treat-
ment response [13]. As reported in other studies
[12,18–22], there is considerable overlap in EBV DNA
loads between the cases and control which made it
impossible to set a cut-off that completely distinguished
lymphoma patients from non-lymphoma patients. In our
study, it is reasonable to conclude that in patients with
an EBV-DNA load >100,000 IU/mL, a search for ARL
seems useful.
EBV-DNA in longitudinal study
Although EBV DNA loads shortly before diagnosis may
be predictive of ARL, serial EBV DNA load measurements
in the 13 HIV-infected patients in this study during the
preceding 12 months before ARL diagnosis showed to
be of poor predictive value for monitoring the develop-
ment of ARL. EBV DNA load 12 months before ARL diag-
nosis was not different from those in HIV positive
controls with opportunistic infections without ARL. The
combination of a disturbed balance between virus and
host, expressed as high EBV-DNA and low nadir CD4þ
cell count <200mm3, may increase the risk of develop-
ment of ARL. Our control patients, also late presenters,
with comparable low CD4þ cells, rate of cART usage and
HIV suppression, may have regained control on EBV
replication, despite the occurrence of opportunistic
infections, and not develop ARL. CD4þ count is a crude
marker of cell-mediated immune function, but they do
not reflect the level of EBV-specific cytotoxic T cell
immunity [12].
There are several limitations to this study. Consistent
with a retrospective nature of the study, the timing of
EBV DNA sample collection was not always optimal and
there were missing data. The number of patients with
longitudinal data was small. Follow-up after treatment
of ARL is missing, which is a failure in understanding the
pathogenic mechanism of ARL. Despite this, our results
suggest that EBV DNA load may be a surrogate marker
of ARL Diagnosis. EBV DNA levels have been shown to
fluctuate over time with low levels, which in HIV-
infected patients may increase rapidly, with an increased
risk of developing ARL.
Conclusions
Our findings suggest that HIV-infected adults with peak
EBV DNA loads above 100,000 IU/mL in plasma or serum
are at approximately 13-fold increased risk of ARL com-
pared to patients with peak EBV DNA loads equal or
below 100,000 IU/mL. Peak EBV DNA load in plasma or
serum is not a predictive biomarker on account of low
sensitivity and specificity. However, with a cut-off point
of 100,000 IU/mL and a corresponding positive predict-
ive value of 77.3%, peak EBV DNA load can be useful in
clinical setting to accelerate time to diagnosis and treat-
ment. EBV-DNA loads in samples taken during the pre-
ceding year of ARL diagnosis showed to be of poor
predictive value. Larger studies are required to confirm
the diagnostic value of this marker and define its prog-
nostic value in ARL treatment in HIV positive patients.
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